Well given the design of the trial - one arm, open label - I highly doubt the results will settle much. Without a control wing, it's just not possible to definitively say what part of the patients' treatment is effective. Hopefully MSB find it in their hearts to publish the full data including patient baselines so that a proper peer reviewed journal can have a good look.
After all, there's no better way to drive physician acceptance than a full dataset, properly peer reviewed unequivocally showing efficacy and safety.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
0.025(1.47%) |
Mkt cap ! $2.207B | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.73 | $1.64 | $4.189M | 2.480M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31201 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 59276 | 6 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |